This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacobson, J. M. Articles by Luft, B. J. Search for Related Content PubMed PubMed Citation Articles by Jacobson, J. M. Articles by Luft, B. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Jun 1996, 1360-1365, Vol 40, No. 6
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii

JM Jacobson, M Davidian, PM Rainey, R Hafner, RH Raasch and BJ Luft
Department of Medicine, Veterans' Affairs Medical Center, Bronx, NY 10468, USA.

Pyrimethamine pharmacokinetics were studied in 11 human immunodeficiency virus (HIV)-positive patients who were seropositive for exposure to Toxoplasma gondii and were taking zidovudine (AIDS Clinical Trials Group Protocol 102). Pyrimethamine was administered at 50 mg daily for 3 weeks to achieve steady state, and pharmacokinetic profiles were determined after administration of the last dose. Noncompartmental and compartmental analyses were performed. Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h. These values are similar to those seen in subjects without HIV infection. Pyrimethamine pharmacokinetics did not differ significantly in those subjects who were intravenous drug users. Adverse effects were noted in 73% of those initially enrolled in this study, leading to discontinuation for 38%. No association was noted between pyrimethamine levels and the incidence of adverse events. No significant differences were seen in zidovudine pharmacokinetic parameters obtained from studies performed before and during treatment with pyrimethamine. In summary, pyrimethamine exhibited pharmacokinetics in HIV-infected patients that were similar to those in non-HIV-infected subjects and it did not alter the pharmacokinetics of zidovudine in these patients.

This article has been cited by other articles:

• Meneceur, P., Bouldouyre, M.-A., Aubert, D., Villena, I., Menotti, J., Sauvage, V., Garin, J.-F., Derouin, F. (2008). In Vitro Susceptibility of Various Genotypic Strains of Toxoplasma gondii to Pyrimethamine, Sulfadiazine, and Atovaquone. Antimicrob. Agents Chemother. 52: 1269-1277 [Abstract] [Full Text]  
• Corvaisier, S., Charpiat, B., Mounier, C., Wallon, M., Leboucher, G., Al Kurdi, M., Chaulet, J.-F., Peyron, F. (2004). Population Pharmacokinetics of Pyrimethamine and Sulfadoxine in Children Treated for Congenital Toxoplasmosis. Antimicrob. Agents Chemother. 48: 3794-3800 [Abstract] [Full Text]  
• Reynolds, M. G., Oh, J., Roos, D. S. (2001). In Vitro Generation of Novel Pyrimethamine Resistance Mutations in the Toxoplasma gondii Dihydrofolate Reductase. Antimicrob. Agents Chemother. 45: 1271-1277 [Abstract] [Full Text]